Toward the rational design of protein kinase casein kinase-2 inhibitors.
Casein kinase-2 (CK2) probably is the most pleiotropic member of the protein kinase family, with more than 200 substrates known to date. Unlike the great majority of protein kinases, which are tightly regulated enzymes, CK2 is endowed with high constitutive activity, a feature that is suspected to underlie its oncogenic potential and possible implication in viral infections. This makes CK2 an attractive target for anti-neoplastic and antiviral drugs. Here, we present an overview of our present knowledge about CK2 inhibitors, with special reference to the information drawn from two recently solved crystal structures of CK2alpha in complex with emodin and with 4,5,6,7-tetrabromo-2-azabenzimidazole (TBB), this latter being the most specific CK2 inhibitor known to date. A comparison with a series of anthraquinone and xanthenone derivatives highlights the crucial relevance of the hydroxyl group at position 3 for inhibition by emodin, and discloses the possibility of increasing the inhibitory potency by placing an electron withdrawing group at position 5. We also present mutational data corroborating the relevance of two hydrophobic residues unique to CK2, Val66 and Ile174, for the interactions with emodin and TBB, but not with the flavonoid inhibitors quercetin and fisetin. In particular, the CK2alpha mutant V66A displays 27- and 11-fold higher IC(50) values with emodin and TBB, respectively, as compared with the wild-type, while the IC(50) value with quercetin is unchanged. The data presented pave the road toward the rational design of more potent and selective inhibitors of CK2 and the generation of CK2 mutants refractory to inhibition, useful to probe the implication of CK2 in specific cellular functions.
Department of Biological Chemistry, CNR Biomembrane Research Center, University of Padova, Viale G. Colombo 3, 35121, Padova, Italy.
Stefania
S
Sarno
Stefano
S
Moro
Flavio
F
Meggio
Giuseppe
G
Zagotto
Diego
D
Dal Ben
Paola
P
Ghisellini
Roberto
R
Battistutta
Giuseppe
G
Zanotti
Lorenzo A
LA
Pinna
D000818:Animals; D047390:Casein Kinase II; D003198:Computer Simulation; D004642:Emodin / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D051381:Rats; D013329:Structure-Activity Relationship; D014230:Triazoles / Q000494:pharmacology
C103118:4,5,6,7-tetrabromo-2-azabenzimidazole; D004791:Enzyme Inhibitors; D014230:Triazoles; D047390:Casein Kinase II; D017346:Protein Serine-Threonine Kinases; D004642:Emodin